Cambinol’s anticancer action in Burkitt lymphoma might be achieved by a combination of BCL6 inactivation and checkpoint activation since acetylation inactivates BCL6 and promotes p53 and additional checkpoint signaling pathways. The gene discussed is BCL6; the disease is Burkitt lymphoma.